(Total Views: 633)
Posted On: 10/01/2020 6:23:43 PM
Post# of 154409
“Either a buyout or a distribution deal for all other indications excluding HIV and COVID-19 (for the next 3 years).”
IMO, I don’t see a BO or distribution deal for any other indication outside of HIV and COVID happening in the near future (if that’s what you were implying). The phase 2 trials for NASH, Alzheimer’s, and Cancer need to at least return good intern analysis data before a decent licensing deal is completed. Considering 2 of the trials haven’t begun yet, and the other (cancer) is enrolling slowly, that could be 1-2 years away with historical enrollment rates (although NP has states Dr. L’s dad has 300-400 patients ready for the Alzheimer’s trial).
IMO, I don’t see a BO or distribution deal for any other indication outside of HIV and COVID happening in the near future (if that’s what you were implying). The phase 2 trials for NASH, Alzheimer’s, and Cancer need to at least return good intern analysis data before a decent licensing deal is completed. Considering 2 of the trials haven’t begun yet, and the other (cancer) is enrolling slowly, that could be 1-2 years away with historical enrollment rates (although NP has states Dr. L’s dad has 300-400 patients ready for the Alzheimer’s trial).
(0)
(0)
